View Older Stories View More Recent Stories

Apr 21, 2020 04:05PM Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
Mar 31, 2020 04:02PM Jazz Pharmaceuticals (JAZZ) Provides COVID-19 Business Update
Mar 31, 2020 04:01PM Jazz Pharmaceuticals Provides COVID-19 Business Update
Mar 25, 2020 04:10PM Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Mar 25, 2020 04:05PM Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Feb 26, 2020 04:05PM Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Feb 25, 2020 04:05PM Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results
Feb 17, 2020 02:30AM PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Feb 11, 2020 04:05PM Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020
Jan 22, 2020 08:00AM Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020 02:30AM PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Jan 20, 2020 10:35AM Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Jan 6, 2020 04:05PM Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 30, 2019 08:02AM Jazz Pharmaceuticals (JAZZ) Reports First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458
Dec 30, 2019 08:00AM Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Dec 19, 2019 08:11AM PharmaMar and Jazz Pharmaceuticals (JAZZ) Sign Exclusive License Agreement for Lurbinectedin in U.S.
Dec 19, 2019 08:00AM PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S.
Nov 15, 2019 06:45AM Jazz Pharmaceuticals (JAZZ) Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or OSA
Nov 15, 2019 06:45AM Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Nov 14, 2019 04:05PM Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Nov 7, 2019 08:00AM Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting
Nov 5, 2019 04:05PM Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results
Oct 22, 2019 04:05PM Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019
Oct 10, 2019 04:16PM Jazz Pharmaceuticals (JAZZ) Reports 1st Patient Enrolled in Ph. 2 Clinical Trial Evaluating Defibrotide for Prevention of CAR-T Associated Neurotoxicity
Oct 10, 2019 04:15PM Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
Sep 30, 2019 08:30AM Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans
Sep 26, 2019 05:58AM Jazz Pharmaceuticals (JAZZ) Highlights Positive JZP-258 Phase 3 Study Data
Sep 25, 2019 08:00PM Jazz Pharmaceuticals Presents Positive JZP-258 Phase 3 Study Data at World Sleep 2019
Sep 18, 2019 04:05PM Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update
Aug 27, 2019 04:05PM Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Aug 12, 2019 04:03PM Jazz Pharmaceuticals (JAZZ) Announces Acquisition of Cavion
Aug 12, 2019 04:01PM Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
Aug 6, 2019 04:05PM Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results
Aug 6, 2019 04:01PM Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
Jul 23, 2019 04:05PM Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
Jul 10, 2019 06:00AM Jazz Pharmaceuticals (JAZZ) Reports Acquisition of Pre-Clinical Pan-RAF Inhibitor Program from Redx Pharma
Jul 10, 2019 02:00AM Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
Jun 25, 2019 04:05PM Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update
Jun 17, 2019 08:02AM Jazz Pharmaceuticals (JAZZ) Receives Schedule IV Designation from DEA for Sunosi
Jun 17, 2019 08:00AM Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol)
Jun 3, 2019 08:00AM Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
May 16, 2019 04:30PM Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
May 9, 2019 08:00AM Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019
May 7, 2019 04:05PM Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
May 6, 2019 04:05PM Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
Apr 23, 2019 04:05PM Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
Mar 26, 2019 04:16PM Jazz (JAZZ) Phase 3 Study of JZP-258 in Adult Narcolepsy Patients Shows Statistically Significant Differences in Primary Endpoint
Mar 26, 2019 04:13PM Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Mar 21, 2019 06:28AM Jazz Pharmaceuticals (JAZZ) Announces FDA Approval for Daytime Sleepiness Drug Sunosi
Mar 20, 2019 06:53PM Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
View More Recent Stories View Older Stories